Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med;370:997-1007. DOI: 10.1056/NEJMoa1315226

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman, Jeff P. Sharman, Steven E. Coutre, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian Flinn, Paolo Ghia, Herbert Eradat, Thomas Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger D. Dansey, Michael Hallek, Susan M. O'Brien

This supplement contains the following items:

Table S1	p. 2
Figure S1	p. 3
Figure S2	p. 4
Ipsos Healthcare Research Study*	
Design	p. 5
Results	p. 6
IntrinsiQ Study*	
Design	p. 16
Results	p. 17

**Study results reprinted with permission from Ipsos Heathcare Research and IntrinsiQ*

Table S1. Patient baseline characteristics and disposition

Characteristic	Idelalisib + R (n=110)	Placebo + R (n=110)
Age, median (range), years	71 (48-90)	71 (47-92)
Gender, males, %	69	62
Disease stage, %		
Rai Stage 0 / I-II / III-IV	0 / 31 / 64	1 / 26 / 65
Binet Stage A+B / C	33 / 57	33 / 55
Extent of CLL, %		
Splenomegaly[a]	79	64
Hepatomegaly[a]	54	57
Anemia (any grade / grade ≥ 3)	75 / 6	72 / 11
Neutropenia (any grade / grade ≥ 3)	34 / 17	35 / 16
Thrombocytopenia (any grade / grade ≥ 3)	62 / 16	61 / 29
ALC, median (range), cells, x 1Kμ/L	32 (0-263)	31 (0-399)
Estimated creatinine clearance, median (range), ml/min	62 (32-161)	67 (23-199)
CLL genetics, %		
Unmutated *IGHV*	83	85
del(17p) or TP53 mutation	42	45
Total CIRS score, median (range)	8 (3-18)	8 (1-18)
Prior agents, median, n (range)	3 (1-12)	3 (1-9)
Rituximab (R), %	91	88
Cyclophosphamide (C) , %	64	70
Fludarabine (F), %	56	64
Bendamustine (B), %	58	54
Chlorambucil (Chl), %	31	22
Prior regimens, %		
BR	46	43
FCR	33	36
R monotherapy	32	31
FR	16	18
Chl monotherapy	18	14
Patient disposition, %		
Randomized	100	100
Ongoing on study	81	52
Discontinued study (investigator determination)		
Disease progression	5	31
Death[b]	3	8
Adverse events	5	5
Physician decision	1	1
Withdrawal by subject	5	3
Other	1	0

a Based on 91 patients in idelalisib + R arm and 90 patients in placebo + R arm with baseline assessment completed

b Does not include 1 death on treatment arm and 4 other deaths on control arm that occurred after patients discontinued the study due to adverse event or progression

Figure S1. KM curves of progression-free survival for select pre-specified patient sub-groups.





Figure S2. Mean change from baseline of laboratory parameters over time.



Ipsos Healthcare Background

Ipsos Healthcare (http://www.ipsos.com/marketing-healthcare/) is a research organization focused on understanding the motivations, behavior and influences of the multiple stakeholders involved in healthcare industry issues. Research in oncology utilizes a large syndicated database of cancer treatment and includes key patient and treatment-related metrics across all tumor types and more than 20 global markets. Specific data collection can be modeled to clarify complex questions including treatment regimen type, initiation and duration of current and prior therapy, as well as maintenance and sequential therapy.

Gilead Project

Gilead Sciences contracted Ipsos Healthcare to collect data from 5 representative countries in the EU to evaluate trend use of agents/regimens across lines of therapy in chronic lymphocytic leukemia during the years 2010, 2011, 2012, through mid-2013.

Methodology

Ipsos Healthcare projected rituximab use as single-agent therapy or part of combination regimens for the treatment of CLL in EU5 Countries (UK, France, Germany, Italy, and Spain) based on patient diaries. Representative panels of cancer treating physicians (N = 509) completed forms directly from reviews of patients' charts and provided information on how many patients in their practices received certain therapies (either mono-therapies or combination regimens). A total of 104 physicians provided CLL patient information across first-, second-, third-line and beyond CLL treatments. According to their most recent annually projected data, a total of 37,119 patients with CLL are estimated to have been treated in the EU5 with anticancer drug therapy between July 2012 and June 2013.

Data Interpretation

According to the data collected on the above patients, there is higher rituximab monotherapy use in later lines of therapy for CLL (first line, 0.3%; second line, 8.2%, third line or more, 22.1%). It should be noted that the data indicate rituximab use in the EU is now more common in clinical practice than chlorambucil use (22.1% vs 9.2%, respectively) as third-line treatment and above in patients with CLL.

The pertinent excerpt of the data follows, including the following tables: 1) 5EU CLL line 2+ regimens (excluding maintenance treatment) and 2) 5EU CLL Line 3+ regimens.

TOC

5EU CLL Line 2+ (excluding line 2 maintenance) regimens
Projected annual treatments

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
Sample base	**392**	**327**	**296**	**329**	**333**	**418**	**480**	**484**	**474**	**438**	**420**
Projected	**10791**	**11233**	**13224**	**14392**	**15225**	**16870**	**16832**	**16588**	**17160**	**15916**	**14974**
Bendamustine/ Rituximab	2094	2781	3528	4027	4057	4455	4776	5401	5683	5078	4943
	19%	*25%*	*27%*	*28%*	*27%*	*26%*	*28%*	*33%*	*33%*	*32%*	*33%*
Cyclophosphamide/ Fludarabine/ Rituximab	2756	2711	2498	2507	2557	3021	3309	3152	3443	2775	2333
	26%	*24%*	*19%*	*17%*	*17%*	*18%*	*20%*	*19%*	*20%*	*17%*	*16%*
Chlorambucil	607	521	1009	1263	1634	1786	1463	1226	1279	1387	1130
	6%	*5%*	*8%*	*9%*	*11%*	*11%*	*9%*	*7%*	*7%*	*9%*	*8%*
Rituximab	303	201	132	152	168	250	478	672	873	1200	1167
	3%	*2%*	*1%*	*1%*	*1%*	*1%*	*3%*	*4%*	*5%*	*8%*	*8%*
Fludarabine	317	236	253	322	313	433	469	545	908	896	793
	3%	*2%*	*2%*	*2%*	*2%*	*3%*	*3%*	*3%*	*5%*	*6%*	*5%*
Bendamustine	202	104	195	262	406	754	863	947	902	740	694
	2%	*1%*	*1%*	*2%*	*3%*	*4%*	*5%*	*6%*	*5%*	*5%*	*5%*
Fludarabine/ Rituximab	155	149	136	136	121	66	53	88	125	329	463
	1%	*1%*	*1%*	*1%*	*1%*	*	*	*1%*	*1%*	*2%*	*3%*
Ofatumumab	102	102	95	110	82	96	140	139	265	333	458
	1%	*1%*	*1%*	*1%*	*1%*	*1%*	*1%*	*1%*	*2%*	*2%*	*3%*
Chlorambucil/ Rituximab	429	329	418	345	532	748	680	611	492	344	381
	4%	*3%*	*3%*	*2%*	*3%*	*4%*	*4%*	*4%*	*3%*	*2%*	*3%*
Chlorambucil/ Prednis(ol)one	377	321	428	509	521	557	389	281	251	341	374
	3%	*3%*	*3%*	*4%*	*3%*	*3%*	*2%*	*2%*	*1%*	*2%*	*2%*
Prednis(ol)one	-	-	198	370	522	672	545	478	442	359	415
	-	-	*1%*	*3%*	*3%*	*4%*	*3%*	*3%*	*3%*	*2%*	*3%*
Alemtuzumab	448	316	394	380	459	548	548	504	412	340	308
	4%	*3%*	*3%*	*3%*	*3%*	*3%*	*3%*	*3%*	*2%*	*2%*	*2%*
Cyclophosphamide/ Doxorubicin/ Prednis(ol)one/ Rituximab/ Vincristine	255	255	218	34	48	68	114	128	117	204	178
	2%	*2%*	*2%*	*	*	*	*1%*	*1%*	*1%*	*1%*	*1%*
Cyclophosphamide/ Prednis(ol)one/ Vincristine	133	239	220	160	177	59	91	55	60	194	163
	1%	*2%*	*2%*	*1%*	*1%*	*	*1%*	*	*	*1%*	*1%*
Cyclophosphamide/ Prednis(ol)one/ Rituximab/ Vincristine	248	290	280	330	348	503	525	379	317	95	93
	2%	*3%*	*2%*	*2%*	*2%*	*3%*	*3%*	*2%*	*2%*	*1%*	*1%*
Melphalan	-	-	-	-	-	-	-	-	34	54	54

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
Melphalan	-	-	-	-	-	-	-	-	*	*	*
Cyclophosphamide/ Methylprednisolone/ Rituximab/ Vincristine	77	-	-	-	83	83	105	105	22	45	43
	1%	-	-	-	*1%*	*	*1%*	*1%*	*	*	*
Mercaptopurine/ Prednis(ol)one	-	-	-	8	8	8	8	-	22	22	41
	-	-	-	*	*	*	*	-	*	*	*
Mercaptopurine/ Rituximab	-	-	-	-	14	43	43	101	108	98	98
	-	-	-	-	*	*	*	*1%*	*1%*	*1%*	*1%*
Cyclophosphamide/ Doxorubicin/ Prednis(ol)one/ Rituximab	-	-	-	-	-	-	-	-	38	38	38
	-	-	-	-	-	-	-	-	*	*	*
Cyclophosphamide/ Pentostatin/ Rituximab	47	85	114	193	160	146	102	22	22	-	36
	*	*1%*	*1%*	*1%*	*1%*	*1%*	*1%*	*	*	-	*
Cisplatin/ Cytarabine	-	-	-	-	-	-	-	-	-	-	33
	-	-	-	-	-	-	-	-	-	-	*
Bendamustine/ Dexamethasone/ Rituximab	33	33	33	33	21	21	21	21	-	-	32
	*	*	*	*	*	*	*	*	-	-	*
Chlorambucil/ Dexamethasone	-	-	-	-	-	-	-	-	-	-	32
	-	-	-	-	-	-	-	-	-	-	*
Bendamustine/ Cytarabine/ Rituximab	-	-	-	-	-	-	-	-	-	-	32
	-	-	-	-	-	-	-	-	-	-	*
Cyclophosphamide/ Rituximab	147	184	262	341	210	172	95	-	-	-	32
	1%	*2%*	*2%*	*2%*	*1%*	*1%*	*1%*	-	-	-	*
Cyclophosphamide/ Fludarabine	441	340	360	471	511	491	423	328	236	238	94
	4%	*3%*	*3%*	*3%*	*3%*	*3%*	*3%*	*2%*	*1%*	*1%*	*1%*
Cyclophosphamide/ Ofatumumab/ Pentostatin	-	-	-	-	-	-	-	-	-	31	31
	-	-	-	-	-	-	-	-	-	*	*
Lenalidomide	18	18	-	27	27	27	27	-	-	-	31
	*	*	-	*	*	*	*	-	-	-	*
Bendamustine/ Methylprednisolone/ Ofatumumab	-	-	-	-	-	-	-	-	-	-	30
	-	-	-	-	-	-	-	-	-	-	*
Doxorubicin	-	-	-	-	-	-	-	-	28	28	28
	-	-	-	-	-	-	-	-	*	*	*
Cyclophosphamide/ Doxorubicin/ Vincristine	54	54	36	36	-	-	-	-	28	28	28
	*	*	*	*	-	-	-	-	*	*	*
Alemtuzumab/ Dexamethasone	20	-	104	104	104	175	71	86	86	14	40
	*	-	*1%*	*1%*	*1%*	*1%*	*	*1%*	*	*	*
Cortisone/ Mercaptopurine	-	-	-	-	-	-	-	7	28	28	28
	-	-	-	-	-	-	-	*	*	*	*
Mercaptopurine/ Prednis(ol)one/ Rituximab	-	-	-	54	54	54	54	64	64	64	83
	-	-	-	*	*	*	*	*	*	*	*1%*

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
Alemtuzumab/ Bendamustine	-	-	-	-	-	-	20	20	20	20	-
	-	-	-	-	-	-	*	*	*	*	-
Alemtuzumab/ Cyclophosphamide/ Doxorubicin/ Methylprednisolone/ Vincristine	33	33	33	33	-	-	-	-	-	-	-
	*	*	*	*	-	-	-	-	-	-	-
Alemtuzumab/ Cyclophosphamide/ Doxorubicin/ Prednis(ol)one/ Vincristine	18	18	-	-	-	-	-	-	-	-	-
	*	*	-	-	-	-	-	-	-	-	-
Alemtuzumab/ Fludarabine	90	90	56	18	-	-	-	-	-	-	-
	1%	*1%*	*	*	-	-	-	-	-	-	-
Alemtuzumab/ Hydrocortisone Sodium Succinate	-	-	-	-	-	22	77	77	77	54	-
	-	-	-	-	-	*	*	*	*	*	-
Alemtuzumab/ Methylprednisolone	-	-	-	21	21	29	49	29	29	20	-
	-	-	-	*	*	*	*	*	*	*	-
Bendamustine/ Dexamethasone	-	-	-	54	104	135	155	101	50	20	-
	-	-	-	*	*1%*	*1%*	*1%*	*1%*	*	*	-
Bendamustine/ Methotrexate/ Rituximab	-	-	79	79	79	79	-	-	-	-	-
	-	-	*1%*	*1%*	*1%*	*	-	-	-	-	-
Bendamustine/ Methylprednisolone	-	-	-	-	-	43	43	43	43	-	-
	-	-	-	-	-	*	*	*	*	-	-
Bendamustine/ Prednis(ol)one	117	117	117	-	-	-	-	-	-	-	-
	1%	*1%*	*1%*	-	-	-	-	-	-	-	-
Bendamustine/ Prednis(ol)one/ Rituximab	75	53	53	-	-	-	-	-	-	-	-
	1%	*	*	-	-	-	-	-	-	-	-
Bortezomib/ Fludarabine/ Imatinib mesylate/ Lenalidomide/ Rituximab	10	10	-	-	-	-	-	-	-	-	-
	*	*	-	-	-	-	-	-	-	-	-
Chlorambucil/ Corticosteroids	-	-	-	-	-	-	31	31	31	31	-
	-	-	-	-	-	-	*	*	*	*	-
Chlorambucil/ Fludarabine/ Rituximab	14	14	14	14	-	-	-	-	-	-	-
	*	*	*	*	-	-	-	-	-	-	-
Chlorambucil/ Methylprednisolone	-	-	-	-	-	25	45	45	45	20	-
	-	-	-	-	-	*	*	*	*	*	-
Chlorambucil/ Prednis(ol)one/ Rituximab	-	127	214	214	290	163	75	75	-	-	-
	-	*1%*	*2%*	*1%*	*2%*	*1%*	*	*	-	-	-
Chlorambucil/ Trial Drug (Cyto)	-	-	-	-	-	-	-	7	7	7	7
	-	-	-	-	-	-	-	*	*	*	*
Cisplatin/ Cytarabine/ Dexamethasone	20	20	20	-	-	-	-	-	-	-	-
	*	*	*	-	-	-	-	-	-	-	-
Cisplatin/ Cytarabine/ Dexamethasone/ Rituximab	10	-	-	-	-	-	-	-	-	-	-
	*	-	-	-	-	-	-	-	-	-	-
Cisplatin/ Cytarabine/ Etoposide/	25	14	14	-	-	-	-	-	-	-	-

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
Methylprednisolone/ Rituximab	*	*	*	-	-	-	-	-	-	-	-
Cisplatin/ Cytarabine/ Etoposide/ Rituximab	10 *	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cladribine	54 *	54 *	204 *2%*	204 *1%*	150 *1%*	150 *1%*	- -	- -	- -	- -	- -
Clomiphene/ Rituximab	14 *	14 *	- -	- -	- -	- -	- -	- -	- -	- -	- -
Corticosteroids/ Mercaptopurine	- -	- -	- -	8 *	8 *	8 *	8 *	- -	- -	- -	- -
Cortisone/ Cyclophosphamide/ Doxorubicin/ Vincristine	- -	- -	- -	46 *	46 *	46 *	46 *	- -	- -	- -	- -
Cortisone/ Mercaptopurine/ Rituximab	- -	- -	- -	- -	- -	- -	14 *	14 *	14 *	14 *	- -
Cyclophosphamide	45 *	33 *	64 *	160 *1%*	144 *1%*	164 *1%*	148 *1%*	52 *	34 *	14 *	- -
Cyclophosphamide/ Dexamethasone	- -	42 *	42 *	42 *	42 *	45 *	45 *	45 *	45 *	- -	- -
Cyclophosphamide/ Dexamethasone/ Rituximab	- -	- -	- -	21 *	21 *	21 *	21 *	90 *1%*	90 *1%*	90 *1%*	90 *1%*
Cyclophosphamide/ Doxorubicin/ Methylprednisolone/ Rituximab/ Vincristine	36 *	36 *	36 *	36 *	- -	- -	- -	- -	- -	- -	- -
Cyclophosphamide/ Doxorubicin/ Prednis(ol)one/ Vincristine	65 *1%*	55 *	55 *	34 *	63 *	63 *	63 *	29 *	- -	- -	- -
Cyclophosphamide/ Doxorubicin/ Rituximab/ Vincristine	10 *	- -	- -	89 *1%*	89 *1%*	89 *1%*	89 *1%*	- -	- -	- -	- -
Cyclophosphamide/ Fludarabine/ Lenalidomide/ Rituximab/ Vincristine	16 *	16 *	16 *	16 *	- -	- -	- -	- -	- -	- -	- -
Cyclophosphamide/ Fludarabine/ Mitoxantrone	67 *1%*	250 *2%*	250 *2%*	250 *2%*	250 *2%*	- -	- -	- -	- -	- -	- -
Cyclophosphamide/ Fludarabine/ Mitoxantrone/ Rituximab	21 *	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cyclophosphamide/ Fludarabine/ Ofatumumab	- -	- -	104 *1%*	104 *1%*	104 *1%*	104 *1%*	- -	62 *	62 *	62 *	62 *
Cyclophosphamide/ Methylprednisolone/ Vincristine	33 *	33 *	33 *	- -	- -	- -	- -	- -	- -	- -	- -
Cyclophosphamide/ Pegylated Liposomal Doxorubicin	10 *	10 *	10 *	10 *	- -	- -	- -	- -	- -	- -	- -
Cyclophosphamide/ Rituximab/ Thalidomide	15 *	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
Cyclophosphamide/ Rituximab/ Vincristine	38	112	112	112	75	-	-	-	-	-	-
	*	*1%*	*1%*	*1%*	*	-	-	-	-	-	-
Cytarabine/ Dexamethasone/ Oxaliplatin	-	90	90	90	90	-	-	-	-	-	-
	-	*1%*	*1%*	*1%*	*1%*	-	-	-	-	-	-
Cytarabine/ Dexamethasone/ Oxaliplatin/ Rituximab	33	33	33	33	-	-	-	-	-	-	-
	*	*	*	*	-	-	-	-	-	-	-
Cytarabine/ Fludarabine/ Rituximab	-	-	27	27	27	27	-	-	-	-	-
	-	-	*	*	*	*	-	-	-	-	-
Dexamethasone	15	-	-	-	-	-	-	-	-	-	-
	*	-	-	-	-	-	-	-	-	-	-
Dexamethasone/ Doxorubicin/ Vincristine	38	38	38	-	-	-	-	-	-	-	-
	*	*	*	-	-	-	-	-	-	-	-
Dexamethasone/ Fludarabine	-	-	-	-	100	100	100	100	-	-	-
	-	-	-	-	*1%*	*1%*	*1%*	*1%*	-	-	-
Dexamethasone/ Fludarabine/ Mitoxantrone/ Rituximab	10	-	-	-	-	-	-	-	-	-	-
	*	-	-	-	-	-	-	-	-	-	-
Dexamethasone/ Rituximab	31	-	-	-	-	30	30	30	30	-	-
	*	-	-	-	-	*	*	*	*	-	-
Etoposide/ Ifosfamide/ Mitoxantrone/ Rituximab	-	-	-	-	-	-	14	14	14	14	-
	-	-	-	-	-	-	*	*	*	*	-
Fludarabine/ Lenalidomide/ Rituximab/ Thalidomide	33	33	18	18	-	-	-	-	-	-	-
	*	*	*	*	-	-	-	-	-	-	-
Fludarabine/ Mitoxantrone/ Rituximab	-	90	193	193	193	104	-	-	-	-	-
	-	*1%*	*1%*	*1%*	*1%*	*1%*	-	-	-	-	-
Fludarabine/ Prednis(ol)one	-	-	-	-	17	17	17	17	-	-	-
	-	-	-	-	*	*	*	*	-	-	-
Fludarabine/ Treosulfan	187	187	157	118	-	-	-	-	-	-	-
	2%	*2%*	*1%*	*1%*	-	-	-	-	-	-	-
Gemcitabine/ Oxaliplatin/ Rituximab	78	78	78	-	-	-	-	-	-	-	-
	1%	*1%*	*1%*	-	-	-	-	-	-	-	-
Gemcitabine/ Vinblastine	93	93	-	-	-	-	-	-	-	-	-
	1%	*1%*	-	-	-	-	-	-	-	-	-
Interferon Alpha 2b	-	-	-	16	16	16	16	-	-	-	-
	-	-	-	*	*	*	*	-	-	-	-
L-Asparaginase/ Methotrexate	33	33	33	33	-	-	-	-	-	-	-
	*	*	*	*	-	-	-	-	-	-	-
Melphalan/ Prednis(ol)one	-	-	-	-	33	33	33	33	-	-	-
	-	-	-	-	*	*	*	*	-	-	-
Mercaptopurine	-	42	42	42	42	9	9	9	9	-	-

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
Mercaptopurine	-	*	*	*	*	*	*	*	*	-	-
Methotrexate	18	18	18	18	-	-	-	-	-	-	-
	*	*	*	*	-	-	-	-	-	-	-
Methylprednisolone	60	60	33	14	-	-	13	13	13	13	-
	1%	*1%*	*	*	-	-	*	*	*	*	-
Methylprednisolone/ Rituximab	-	-	-	-	-	-	105	105	105	105	-
	-	-	-	-	-	-	*1%*	*1%*	*1%*	*1%*	-
Pentostatin	-	-	-	8	59	59	59	50	-	-	-
	-	-	-	*	*	*	*	*	-	-	-
Pentostatin/ Rituximab	19	19	19	19	-	30	30	30	30	-	-
	*	*	*	*	-	*	*	*	*	-	-
Prednis(ol)one/ Rituximab	-	-	-	15	15	15	15	40	40	40	40
	-	-	-	*	*	*	*	*	*	*	*
Rituximab/ Temsirolimus	-	-	8	8	8	8	-	-	-	-	-
	-	-	*	*	*	*	-	-	-	-	-
Temozolomide	31	-	-	-	-	-	-	-	-	-	-
	*	-	-	-	-	-	-	-	-	-	-
Trial Drug (Bio)	-	-	-	-	-	-	71	87	87	87	17
	-	-	-	-	-	-	*	*1%*	*1%*	*1%*	*

TOC

5EU CLL Line 3+ regimens
Projected annual treatments

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
Sample base	**140**	**117**	**106**	**109**	**99**	**125**	**129**	**125**	**126**	**124**	**134**
Projected	**3947**	**4284**	**5090**	**5199**	**4973**	**5250**	**4799**	**4696**	**4946**	**5103**	**5163**
Bendamustine/ Rituximab	799	1015	1353	1575	1313	1370	1284	1469	1737	1651	1598
	20%	*24%*	*27%*	*30%*	*26%*	*26%*	*27%*	*31%*	*35%*	*32%*	*31%*
Rituximab	145	66	9	85	102	199	405	573	781	1112	1141
	4%	*2%*	*	*2%*	*2%*	*4%*	*8%*	*12%*	*16%*	*22%*	*22%*
Chlorambucil	248	225	348	365	400	465	369	409	457	504	473
	6%	*5%*	*7%*	*7%*	*8%*	*9%*	*8%*	*9%*	*9%*	*10%*	*9%*
Ofatumumab	102	102	95	110	67	82	115	83	171	212	333
	3%	*2%*	*2%*	*2%*	*1%*	*2%*	*2%*	*2%*	*3%*	*4%*	*6%*
Prednis(ol)one	-	-	198	316	413	489	362	320	340	331	366
	-	-	*4%*	*6%*	*8%*	*9%*	*8%*	*7%*	*7%*	*6%*	*7%*
Fludarabine/ Rituximab	90	41	-	-	-	-	-	-	-	118	151
	2%	*1%*	-	-	-	-	-	-	-	*2%*	*3%*
Cyclophosphamide/ Doxorubicin/ Prednis(ol)one/ Rituximab/ Vincristine	170	170	185	34	48	48	33	47	14	122	156
	4%	*4%*	*4%*	*1%*	*1%*	*1%*	*1%*	*1%*	*	*2%*	*3%*
Bendamustine	97	74	61	61	77	124	114	212	179	191	239
	2%	*2%*	*1%*	*1%*	*2%*	*2%*	*2%*	*5%*	*4%*	*4%*	*5%*
Fludarabine	77	56	50	92	73	96	65	55	128	173	173
	2%	*1%*	*1%*	*2%*	*1%*	*2%*	*1%*	*1%*	*3%*	*3%*	*3%*
Chlorambucil/ Rituximab	186	125	157	53	103	222	190	169	119	68	101
	5%	*3%*	*3%*	*1%*	*2%*	*4%*	*4%*	*4%*	*2%*	*1%*	*2%*
Chlorambucil/ Prednis(ol)one	151	155	241	251	281	317	225	169	105	62	50
	4%	*4%*	*5%*	*5%*	*6%*	*6%*	*5%*	*4%*	*2%*	*1%*	*1%*
Cyclophosphamide/ Pentostatin/ Rituximab	33	33	33	33	-	22	22	22	22	-	36
	1%	*1%*	*1%*	*1%*	-	*	*	*	*	-	*1%*
Cisplatin/ Cytarabine	-	-	-	-	-	-	-	-	-	-	33
	-	-	-	-	-	-	-	-	-	-	*1%*
Bendamustine/ Cytarabine/ Rituximab	-	-	-	-	-	-	-	-	-	-	32
	-	-	-	-	-	-	-	-	-	-	*1%*
Lenalidomide	18	18	-	27	27	27	27	-	-	-	31
	*	*	-	*1%*	*1%*	*1%*	*1%*	-	-	-	*1%*
Doxorubicin	-	-	-	-	-	-	-	-	28	28	28

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
~~Doxorubicin~~	-	-	-	-	-	-	-	-	*1%*	*1%*	*1%*
Alemtuzumab	261	211	236	117	152	188	164	163	118	92	81
	7%	*5%*	*5%*	*2%*	*3%*	*4%*	*3%*	*3%*	*2%*	*2%*	*2%*
Cyclophosphamide/ Prednis(ol)one/ Rituximab/ Vincristine	101	63	63	-	71	211	211	211	140	23	23
	3%	*1%*	*1%*	-	*1%*	*4%*	*4%*	*4%*	*3%*	*	*
Mercaptopurine/ Prednis(ol)one/ Rituximab	-	-	-	-	-	-	-	-	-	-	19
	-	-	-	-	-	-	-	-	-	-	*
Mercaptopurine/ Rituximab	-	-	-	-	-	9	9	9	9	18	18
	-	-	-	-	-	*	*	*	*	*	*
Alemtuzumab/ Bendamustine	-	-	-	-	-	-	20	20	20	20	-
	-	-	-	-	-	-	*	*	*	*	-
Alemtuzumab/ Cyclophosphamide/ Doxorubicin/ Prednis(ol)one/ Vincristine	18	18	-	-	-	-	-	-	-	-	-
	*	*	-	-	-	-	-	-	-	-	-
Alemtuzumab/ Dexamethasone	-	-	104	104	104	104	-	-	-	-	-
	-	-	*2%*	*2%*	*2%*	*2%*	-	-	-	-	-
Alemtuzumab/ Fludarabine	56	56	56	18	-	-	-	-	-	-	-
	1%	*1%*	*1%*	*	-	-	-	-	-	-	-
Alemtuzumab/ Hydrocortisone Sodium Succinate	-	-	-	-	-	22	77	77	77	54	-
	-	-	-	-	-	*	*2%*	*2%*	*2%*	*1%*	-
Bendamustine/ Dexamethasone	-	-	-	54	104	135	155	101	50	20	-
	-	-	-	*1%*	*2%*	*3%*	*3%*	*2%*	*1%*	*	-
Bendamustine/ Dexamethasone/ Rituximab	33	33	33	33	21	21	21	21	-	-	-
	1%	*1%*	*1%*	*1%*	*	*	*	*	-	-	-
Bendamustine/ Methylprednisolone	-	-	-	-	-	43	43	43	43	-	-
	-	-	-	-	-	*1%*	*1%*	*1%*	*1%*	-	-
Bendamustine/ Prednis(ol)one	117	117	117	-	-	-	-	-	-	-	-
	3%	*3%*	*2%*	-	-	-	-	-	-	-	-
Bortezomib/ Fludarabine/ Imatinib mesylate/ Lenalidomide/ Rituximab	10	10	-	-	-	-	-	-	-	-	-
	*	*	-	-	-	-	-	-	-	-	-
Chlorambucil/ Corticosteroids	-	-	-	-	-	-	31	31	31	31	-
	-	-	-	-	-	-	*1%*	*1%*	*1%*	*1%*	-
Chlorambucil/ Prednis(ol)one/ Rituximab	-	127	127	127	127	-	-	-	-	-	-
	-	*3%*	*2%*	*2%*	*3%*	-	-	-	-	-	-
Cisplatin/ Cytarabine/ Dexamethasone	20	20	20	-	-	-	-	-	-	-	-
	1%	*	*	-	-	-	-	-	-	-	-
Cisplatin/ Cytarabine/ Dexamethasone/ Rituximab	10	-	-	-	-	-	-	-	-	-	-
	*	-	-	-	-	-	-	-	-	-	-
Cisplatin/ Cytarabine/ Etoposide/ Methylprednisolone/ Rituximab	14	14	14	-	-	-	-	-	-	-	-
	*	*	*	-	-	-	-	-	-	-	-

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
Cladribine	-	-	150	150	150	150	-	-	-	-	-
	-	-	*3%*	*3%*	*3%*	*3%*	-	-	-	-	-
Corticosteroids/ Mercaptopurine	-	-	-	8	8	8	8	-	-	-	-
	-	-	-	*	*	*	*	-	-	-	-
Cyclophosphamide	12	-	31	127	127	127	110	14	14	14	-
	*	-	*1%*	*2%*	*3%*	*2%*	*2%*	*	*	*	-
Cyclophosphamide/ Dexamethasone	-	42	42	42	42	20	20	20	20	-	-
	-	*1%*	*1%*	*1%*	*1%*	*	*	*	*	-	-
Cyclophosphamide/ Doxorubicin/ Methylprednisolone/ Rituximab/ Vincristine	36	36	36	36	-	-	-	-	-	-	-
	1%	*1%*	*1%*	*1%*	-	-	-	-	-	-	-
Cyclophosphamide/ Doxorubicin/ Prednis(ol)one/ Vincristine	39	39	39	34	63	63	63	29	-	-	-
	1%	*1%*	*1%*	*1%*	*1%*	*1%*	*1%*	*1%*	-	-	-
Cyclophosphamide/ Doxorubicin/ Rituximab/ Vincristine	-	-	-	89	89	89	89	-	-	-	-
	-	-	-	*2%*	*2%*	*2%*	*2%*	-	-	-	-
Cyclophosphamide/ Doxorubicin/ Vincristine	36	36	36	36	-	-	-	-	-	-	-
	1%	*1%*	*1%*	*1%*	-	-	-	-	-	-	-
Cyclophosphamide/ Fludarabine	12	-	62	118	118	118	111	117	117	117	62
	*	-	*1%*	*2%*	*2%*	*2%*	*2%*	*2%*	*2%*	*2%*	*1%*
Cyclophosphamide/ Fludarabine/ Mitoxantrone	-	250	250	250	250	-	-	-	-	-	-
	-	*6%*	*5%*	*5%*	*5%*	-	-	-	-	-	-
Cyclophosphamide/ Fludarabine/ Rituximab	451	422	320	204	200	255	228	178	95	39	-
	11%	*10%*	*6%*	*4%*	*4%*	*5%*	*5%*	*4%*	*2%*	*1%*	-
Cyclophosphamide/ Methylprednisolone/ Rituximab/ Vincristine	77	-	-	-	-	-	-	-	-	-	-
	2%	-	-	-	-	-	-	-	-	-	-
Cyclophosphamide/ Methylprednisolone/ Vincristine	33	33	33	-	-	-	-	-	-	-	-
	1%	*1%*	*1%*	-	-	-	-	-	-	-	-
Cyclophosphamide/ Pegylated Liposomal Doxorubicin	10	10	10	10	-	-	-	-	-	-	-
	*	*	*	*	-	-	-	-	-	-	-
Cyclophosphamide/ Prednis(ol)one/ Vincristine	19	94	75	84	84	8	8	-	-	-	-
	*	*2%*	*1%*	*2%*	*2%*	*	*	-	-	-	-
Cyclophosphamide/ Rituximab	16	53	131	210	210	172	95	-	-	-	-
	*	*1%*	*3%*	*4%*	*4%*	*3%*	*2%*	-	-	-	-
Cyclophosphamide/ Rituximab/ Thalidomide	15	-	-	-	-	-	-	-	-	-	-
	*	-	-	-	-	-	-	-	-	-	-
Cytarabine/ Dexamethasone/ Oxaliplatin	-	90	90	90	90	-	-	-	-	-	-
	-	*2%*	*2%*	*2%*	*2%*	-	-	-	-	-	-
Cytarabine/ Dexamethasone/ Oxaliplatin/ Rituximab	33	33	33	33	-	-	-	-	-	-	-
	1%	*1%*	*1%*	*1%*	-	-	-	-	-	-	-
Dexamethasone	15	-	-	-	-	-	-	-	-	-	-

	Jan 10 - Dec 10	Apr 10 - Mar 11	Jul 10 - Jun 11	Oct 10 - Sep 11	Jan 11 - Dec 11	Apr 11 - Mar 12	Jul 11 - Jun 12	Oct 11 - Sep 12	Jan 12 - Dec 12	Apr 12 - Mar 13	Jul 12 - Jun 13
~~Dexamethasone~~	*	-	-	-	-	-	-	-	-	-	-
Dexamethasone/ Rituximab	-	-	-	-	-	30	30	30	30	-	-
	-	-	-	-	-	*1%*	*1%*	*1%*	*1%*	-	-
Etoposide/ Ifosfamide/ Mitoxantrone/ Rituximab	-	-	-	-	-	-	14	14	14	14	-
	-	-	-	-	-	-	*	*	*	*	-
Fludarabine/ Lenalidomide/ Rituximab/ Thalidomide	15	15	-	-	-	-	-	-	-	-	-
	*	*	-	-	-	-	-	-	-	-	-
Fludarabine/ Treosulfan	172	172	157	118	-	-	-	-	-	-	-
	4%	*4%*	*3%*	*2%*	-	-	-	-	-	-	-
Gemcitabine/ Vinblastine	93	93	-	-	-	-	-	-	-	-	-
	2%	*2%*	-	-	-	-	-	-	-	-	-
L-Asparaginase/ Methotrexate	33	33	33	33	-	-	-	-	-	-	-
	1%	*1%*	*1%*	*1%*	-	-	-	-	-	-	-
Mercaptopurine	-	42	42	42	42	-	-	-	-	-	-
	-	*1%*	*1%*	*1%*	*1%*	-	-	-	-	-	-
Mercaptopurine/ Prednis(ol)one	-	-	-	8	8	8	8	-	-	-	-
	-	-	-	*	*	*	*	-	-	-	-
Methylprednisolone	40	40	14	14	-	-	-	-	-	-	-
	1%	*1%*	*	*	-	-	-	-	-	-	-
Rituximab/ Temsirolimus	-	-	8	8	8	8	-	-	-	-	-
	-	-	*	*	*	*	-	-	-	-	-
Temozolomide	31	-	-	-	-	-	-	-	-	-	-
	1%	-	-	-	-	-	-	-	-	-	-
Trial Drug (Bio)	-	-	-	-	-	-	71	87	87	87	17
	-	-	-	-	-	-	*1%*	*2%*	*2%*	*2%*	*

IntrinsiQ Background

IntrinsiQ (http://www.intrinsiq.com/) (Division of AmerisourceBergen Specialty Group, Burlington, MA) is a research organization that seeks to improve the quality and understanding of cancer care through the use of the clinical software, IntelliDose®, that tracks and manages complex chemotherapy workflows across practices. The software implementations and knowledge gained are utilized to assist pharmaceutical companies improve their R&D process.

The data gathered via IntelliDose® is entered by 820 Medical, Pediatric, Gynecologic and Hematologic Oncologists who use the application in their practice. The composition of IntelliDose® users is much like the overall population of Oncologists who practice in the US with respect to specialty, size of practice, type of practice and geographic location.



Gilead Project

Gilead Sciences contracted IntrinsiQ to collect data from US to evaluate trend use of agents/regimens, including Rituximab, across lines of therapy in chronic lymphocytic leukemia during the years 2010 (starting in August), 2011, 2012 and through July 2013.

Methodology

IntrinsiQ, in real time, at the time of care, collects and processes electronic *longitudinal* treatment records for 57,000 cancer patient treatments each year, which allows access to monthly updates of actual oncology data for epidemiology. The IntrinsiQ Data Warehouse contains information covering approximately 110,000 cancer patients and over 6.7 million administrations of drug therapy.

Data Interpretation

The monthly actual use of regimens for the treatment of CLL in the US over a time period of 36 months (from August 2010 to July 2013) showed that single-agent rituximab is the second most common regimen (18% to 25% of monthly use) for the treatment of CLL across all lines of therapy, with bendamustine + rituximab being the most common regimen used (14% to32% of monthly use). Rituximab monotherapy is also the second most commonly used regimen (7% to16% of monthly use) for the treatment of relapsed CLL after the combination of bendamustine + rituximab (18% to 33% of monthly use).

IntrinsiQ Research 8/15/2013 4:04:38 AM

Diag Combo LOT Monthly (Maintenance Rituximab)

diagnosis: leukemia chronic lymphocytic (CLL adult)

Line of Therapy: second line plus

	Aug-10	Sep-10	Oct-10	Nov-10	Dec-10	Jan-11	Feb-11	Mar-11	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11	Nov-11	Dec-11
IntelliDose Patients	130	124	128	131	111	117	109	118	129	134	157	154	156	153	173	156	177
Projected Patients	3493	3278	3338	3322	2781	2877	2804	2896	3249	3259	3728	3718	3737	3638	4021	3471	4077
	Aug-10	Sep-10	Oct-10	Nov-10	Dec-10	Jan-11	Feb-11	Mar-11	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11	Nov-11	Dec-11
bendamustine - rituximab	724	766	780	683	653	517	671	640	810	805	809	844	1056	1047	955	758	943
	20.7%	23.4%	23.4%	20.6%	23.5%	18.0%	23.9%	22.1%	24.9%	24.7%	21.7%	22.7%	28.3%	28.8%	23.8%	21.8%	23.1%
rituximab	456	343	338	380	201	221	310	394	455	439	476	458	456	381	652	535	506
	13.0%	10.5%	10.1%	11.4%	7.2%	7.7%	11.0%	13.6%	14.0%	13.5%	12.8%	12.3%	12.2%	10.5%	16.2%	15.4%	12.4%
bendamustine	241	370	364	202	226	369	413	246	354	268	333	241	216	190	140	67	92
	6.9%	11.3%	10.9%	6.1%	8.1%	12.8%	14.7%	8.5%	10.9%	8.2%	8.9%	6.5%	5.8%	5.2%	3.5%	1.9%	2.3%
chlorambucil	358	294	350	309	346	342	326	337	314	363	374	398	367	373	326	323	371
	10.2%	9.0%	10.5%	9.3%	12.5%	11.9%	11.6%	11.6%	9.7%	11.1%	10.0%	10.7%	9.8%	10.2%	8.1%	9.3%	9.1%
cyclophosphamide - fludarabine - rituximab	295	264	286	481	377	344	232	271	304	195	262	362	384	238	326	290	253
	8.4%	8.1%	8.6%	14.5%	13.5%	12.0%	8.3%	9.3%	9.3%	6.0%	7.0%	9.7%	10.3%	6.5%	8.1%	8.4%	6.2%
lenalidomide	0	54	76	54	0	0	0	0	0	164	331	379	370	361	364	360	555
	0.0%	1.6%	2.3%	1.6%	0.0%	0.0%	0.0%	0.0%	0.0%	5.0%	8.9%	10.2%	9.9%	9.9%	9.0%	10.4%	13.6%
ofatumumab	134	158	182	127	50	49	52	25	25	49	24	48	24	24	70	89	92
	3.8%	4.8%	5.5%	3.8%	1.8%	1.7%	1.8%	0.8%	0.8%	1.5%	0.6%	1.3%	0.6%	0.7%	1.7%	2.6%	2.3%
fludarabine	188	185	156	101	50	74	52	123	101	146	119	145	144	190	163	89	161
	5.4%	5.6%	4.7%	3.0%	1.8%	2.6%	1.8%	4.2%	3.1%	4.5%	3.2%	3.9%	3.9%	5.2%	4.1%	2.6%	3.9%
fludarabine - rituximab	295	264	104	177	151	148	155	148	152	122	167	121	96	71	210	156	207
	8.4%	8.1%	3.1%	5.3%	5.4%	5.1%	5.5%	5.1%	4.7%	3.7%	4.5%	3.2%	2.6%	2.0%	5.2%	4.5%	5.1%
cyclophosphamide - rituximab - vincristine	54	106	104	127	176	74	52	25	76	49	48	24	72	71	47	67	69
	1.5%	3.2%	3.1%	3.8%	6.3%	2.6%	1.8%	0.8%	2.3%	1.5%	1.3%	0.6%	1.9%	2.0%	1.2%	1.9%	1.7%
cyclophosphamide - doxorubicin - rituximab - vincristine	27	0	26	51	50	49	26	49	101	49	71	72	48	71	47	89	115
	0.8%	0.0%	0.8%	1.5%	1.8%	1.7%	0.9%	1.7%	3.1%	1.5%	1.9%	1.9%	1.3%	2.0%	1.2%	2.6%	2.8%
investigational drugs	27	0	26	0	0	25	0	0	25	0	0	24	0	24	0	22	0
	0.8%	0.0%	0.8%	0.0%	0.0%	0.9%	0.0%	0.0%	0.8%	0.0%	0.0%	0.6%	0.0%	0.7%	0.0%	0.6%	0.0%
azacitidine	0	0	0	0	0	0	0	0	0	0	0	0	48	48	47	67	46
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.3%	1.3%	1.2%	1.9%	1.1%
carboplatin - paclitaxel	0	0	26	51	25	25	26	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.8%	1.5%	0.9%	0.9%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - vincristine	80	0	26	51	50	74	52	49	25	0	95	72	48	24	0	0	0
	2.3%	0.0%	0.8%	1.5%	1.8%	2.6%	1.8%	1.7%	0.8%	0.0%	2.6%	1.9%	1.3%	0.7%	0.0%	0.0%	0.0%
cyclophosphamide - fludarabine	27	26	26	25	0	98	103	49	76	98	71	24	24	48	117	112	69
	0.8%	0.8%	0.8%	0.8%	0.0%	3.4%	3.7%	1.7%	2.3%	3.0%	1.9%	0.6%	0.6%	1.3%	2.9%	3.2%	1.7%
alemtuzumab	80	53	52	127	75	123	77	98	101	73	95	72	48	24	23	0	0
	2.3%	1.6%	1.6%	3.8%	2.7%	4.3%	2.8%	3.4%	3.1%	2.2%	2.6%	1.9%	1.3%	0.7%	0.6%	0.0%	0.0%
cyclophosphamide - rituximab	107	79	52	51	25	25	26	98	76	98	95	121	48	71	23	112	69
	3.1%	2.4%	1.6%	1.5%	0.9%	0.9%	0.9%	3.4%	2.3%	3.0%	2.6%	3.2%	1.3%	2.0%	0.6%	3.2%	1.7%
chlorambucil - rituximab	27	53	52	51	0	0	0	0	0	0	24	24	24	24	23	0	0
	0.8%	1.6%	1.6%	1.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.6%	0.6%	0.7%	0.6%	0.0%	0.0%

	Aug-10	Sep-10	Oct-10	Nov-10	Dec-10	Jan-11	Feb-11	Mar-11	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11	Nov-11	Dec-11
IntelliDose Patients	130	124	128	131	111	117	109	118	129	134	157	154	156	153	173	156	177
Projected Patients	3493	3278	3338	3322	2781	2877	2804	2896	3249	3259	3728	3718	3737	3638	4021	3471	4077
	Aug-10	**Sep-10**	**Oct-10**	**Nov-10**	**Dec-10**	**Jan-11**	**Feb-11**	**Mar-11**	**Apr-11**	**May-11**	**Jun-11**	**Jul-11**	**Aug-11**	**Sep-11**	**Oct-11**	**Nov-11**	**Dec-11**
cyclophosphamide	0	0	26	0	25	49	26	25	0	0	24	24	0	24	23	22	23
	0.0%	0.0%	0.8%	0.0%	0.9%	1.7%	0.9%	0.8%	0.0%	0.0%	0.6%	0.6%	0.0%	0.7%	0.6%	0.6%	0.6%
cyclophosphamide - doxorubicin - vincristine	27	26	0	0	0	0	0	25	0	24	24	24	24	24	23	22	46
	0.8%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.8%	0.0%	0.7%	0.6%	0.6%	0.6%	0.7%	0.6%	0.6%	1.1%
alemtuzumab - rituximab	0	0	0	0	0	0	0	0	0	24	24	24	24	0	0	0	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.6%	0.6%	0.0%	0.0%	0.0%	0.6%
brentuximab vedotin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
decitabine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
carboplatin - etoposide - ifosfamide - rituximab	0	0	52	0	0	25	0	0	0	0	0	0	0	0	23	0	0
	0.0%	0.0%	1.6%	0.0%	0.0%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%
cyclophosphamide - mitoxantrone - rituximab - vincristine	0	0	0	25	50	25	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.8%	1.8%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cisplatin	0	0	0	0	0	0	0	0	0	0	0	24	24	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.6%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - pentostatin - rituximab	54	26	52	0	25	25	26	74	51	24	24	48	72	71	117	112	46
	1.5%	0.8%	1.6%	0.0%	0.9%	0.9%	0.9%	2.5%	1.6%	0.7%	0.6%	1.3%	1.9%	2.0%	2.9%	3.2%	1.1%
dasatinib	0	0	0	25	25	25	26	25	25	24	24	24	24	24	23	22	23
	0.0%	0.0%	0.0%	0.8%	0.9%	0.9%	0.9%	0.9%	0.8%	0.7%	0.6%	0.6%	0.6%	0.7%	0.6%	0.6%	0.6%
bortezomib	54	26	0	51	25	25	26	0	25	24	24	0	0	0	0	0	0
	1.5%	0.8%	0.0%	1.5%	0.9%	0.9%	0.9%	0.0%	0.8%	0.7%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
nilotinib	0	26	26	25	25	25	26	25	0	0	0	0	0	0	0	0	23
	0.0%	0.8%	0.8%	0.8%	0.9%	0.9%	0.9%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
cyclophosphamide - doxorubicin - etoposide - rituximab - vincristine	0	0	0	25	25	0	0	49	51	49	24	0	0	24	23	22	0
	0.0%	0.0%	0.0%	0.8%	0.9%	0.0%	0.0%	1.7%	1.6%	1.5%	0.6%	0.0%	0.0%	0.7%	0.6%	0.6%	0.0%
bleomycin - dacarbazine - doxorubicin - vinblastine	54	26	0	0	0	0	0	0	0	24	24	24	24	24	23	0	0
	1.5%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.6%	0.6%	0.7%	0.6%	0.0%	0.0%
fludarabine - mitoxantrone	0	0	0	0	0	0	0	0	0	0	0	24	24	24	47	45	46
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.6%	0.7%	1.2%	1.3%	1.1%
bendamustine - mitoxantrone - rituximab	0	26	26	0	0	0	0	0	0	0	0	0	0	24	47	0	23
	0.0%	0.8%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	1.2%	0.0%	0.6%
gemcitabine - paclitaxel	0	0	0	0	0	0	0	0	0	24	24	24	24	24	23	22	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.6%	0.6%	0.7%	0.6%	0.6%	0.6%
pemetrexed	0	0	0	0	0	0	0	0	0	0	0	0	0	24	23	22	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.6%	0.6%
carboplatin - etoposide	0	0	26	25	25	49	26	25	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.8%	0.8%	0.9%	1.7%	0.9%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
hydroxyurea - rituximab	0	0	26	25	25	25	26	25	0	24	0	0	0	0	0	0	0
	0.0%	0.0%	0.8%	0.8%	0.9%	0.9%	0.9%	0.8%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - doxorubicin - rituximab	27	26	26	25	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.8%	0.8%	0.8%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
pentostatin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	23	22	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.6%	0.6%

	Aug-10	Sep-10	Oct-10	Nov-10	Dec-10	Jan-11	Feb-11	Mar-11	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11	Nov-11	Dec-11
IntelliDose Patients	130	124	128	131	111	117	109	118	129	134	157	154	156	153	173	156	177
Projected Patients	3493	3278	3338	3322	2781	2877	2804	2896	3249	3259	3728	3718	3737	3638	4021	3471	4077
	Aug-10	**Sep-10**	**Oct-10**	**Nov-10**	**Dec-10**	**Jan-11**	**Feb-11**	**Mar-11**	**Apr-11**	**May-11**	**Jun-11**	**Jul-11**	**Aug-11**	**Sep-11**	**Oct-11**	**Nov-11**	**Dec-11**
carboplatin - etoposide - ifosfamide	27	26	26	0	0	0	0	0	25	24	0	0	0	0	0	0	0
	0.8%	0.8%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.8%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - fludarabine - methotrexate - rituximab	0	0	0	0	0	25	26	25	25	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	0.9%	0.8%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cisplatin - etoposide - ifosfamide - irinotecan	0	0	0	0	0	0	0	0	0	24	24	24	24	24	23	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.6%	0.6%	0.7%	0.6%	0.0%	0.0%
ofatumumab - rituximab	0	0	0	0	0	0	0	0	25	24	0	0	0	0	23	22	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.8%	0.7%	0.0%	0.0%	0.0%	0.0%	0.6%	0.6%	0.6%
fluorouracil - oxaliplatin	27	26	26	25	25	0	0	0	0	0	0	0	0	0	0	0	0
	0.8%	0.8%	0.8%	0.8%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
gemcitabine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
fluorouracil	0	0	0	0	0	0	0	0	0	0	0	24	0	0	0	0	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.6%
cisplatin - docetaxel	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
cisplatin - cytarabine - etoposide	0	0	0	0	0	0	26	25	25	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	0.8%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
bevacizumab - carboplatin - pemetrexed	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
cyclophosphamide - ofatumumab	0	0	0	25	0	25	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.8%	0.0%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cytarabine - methotrexate	0	0	0	0	25	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
paclitaxel	0	0	0	0	0	0	0	0	0	24	24	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
hydroxyurea	0	0	0	0	0	0	0	0	0	0	0	0	0	24	23	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.0%	0.0%
bleomycin - rituximab - vincristine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
bortezomib - cyclophosphamide	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	23
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
bevacizumab - carboplatin - paclitaxel	27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - doxorubicin	27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
fludarabine - ofatumumab	27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
gemcitabine - oxaliplatin - rituximab	27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - methotrexate	0	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

	Aug-10	Sep-10	Oct-10	Nov-10	Dec-10	Jan-11	Feb-11	Mar-11	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11	Nov-11	Dec-11
IntelliDose Patients	130	124	128	131	111	117	109	118	129	134	157	154	156	153	173	156	177
Projected Patients	3493	3278	3338	3322	2781	2877	2804	2896	3249	3259	3728	3718	3737	3638	4021	3471	4077
	Aug-10	**Sep-10**	**Oct-10**	**Nov-10**	**Dec-10**	**Jan-11**	**Feb-11**	**Mar-11**	**Apr-11**	**May-11**	**Jun-11**	**Jul-11**	**Aug-11**	**Sep-11**	**Oct-11**	**Nov-11**	**Dec-11**
alemtuzumab - cyclophosphamide - fludarabine	0	0	0	0	25	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cisplatin - etoposide	0	0	0	0	0	0	0	25	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
carboplatin - pemetrexed	0	0	0	0	0	0	0	0	0	0	24	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
carmustine - cytarabine - etoposide - melphalan	0	0	0	0	0	0	0	0	0	0	24	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - epirubicin - rituximab - vincristine	0	0	0	0	0	0	0	0	0	0	0	0	0	24	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%
decitabine - lenalidomide	0	0	0	0	0	0	0	0	0	0	24	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

IntrinsiQ Research

Diag Combo LOT Monthly (Maintenance Rituximab)

diagnosis: leukemia chronic lymphocytic (CLL adult)

Line of Therapy: second line plus

	Jan-12	Feb-12	Mar-12	Apr-12	May-12	Jun-12	Jul-12	Aug-12	Sep-12	Oct-12	Nov-12	Dec-12	Jan-13	Feb-13	Mar-13	Apr-13	May-13	Jun-13	Jul-13
IntelliDose Patients	185	190	184	160	166	153	127	153	139	128	136	135	163	145	148	136	156	138	162
Projected Patients	4055	4388	4275	3925	4028	3709	3178	3950	3779	3247	3316	3329	4081	3747	3855	3425	3761	3529	3947
	Jan-12	Feb-12	Mar-12	Apr-12	May-12	Jun-12	Jul-12	Aug-12	Sep-12	Oct-12	Nov-12	Dec-12	Jan-13	Feb-13	Mar-13	Apr-13	May-13	Jun-13	Jul-13
bendamustine - rituximab	723	1063	951	959	1016	923	625	958	874	813	826	889	1175	1084	1253	879	988	969	927
	17.8%	24.2%	22.2%	24.4%	25.2%	24.9%	19.7%	24.3%	23.1%	25.0%	24.9%	26.7%	28.8%	28.9%	32.5%	25.7%	26.3%	27.5%	23.5%
rituximab	350	508	557	467	557	510	350	544	491	406	365	445	525	361	496	427	410	485	561
	8.6%	11.6%	13.0%	11.9%	13.8%	13.8%	11.0%	13.8%	13.0%	12.5%	11.0%	13.4%	12.9%	9.6%	12.9%	12.5%	10.9%	13.7%	14.2%
bendamustine	197	208	255	246	290	243	175	181	300	152	243	222	350	361	209	351	289	306	342
	4.9%	4.7%	6.0%	6.3%	7.2%	6.6%	5.5%	4.6%	7.9%	4.7%	7.3%	6.7%	8.6%	9.6%	5.4%	10.3%	7.7%	8.7%	8.7%
chlorambucil	358	370	409	459	475	428	437	457	423	403	417	358	431	447	443	418	362	327	291
	8.8%	8.4%	9.6%	11.7%	11.8%	11.5%	13.8%	11.6%	11.2%	12.4%	12.6%	10.8%	10.6%	11.9%	11.5%	12.2%	9.6%	9.3%	7.4%
cyclophosphamide - fludarabine - rituximab	329	347	325	221	315	267	275	259	246	203	292	272	175	77	235	151	241	204	268
	8.1%	7.9%	7.6%	5.6%	7.8%	7.2%	8.7%	6.6%	6.5%	6.3%	8.8%	8.2%	4.3%	2.1%	6.1%	4.4%	6.4%	5.8%	6.8%
lenalidomide	565	530	503	317	311	317	291	255	217	204	203	80	75	75	72	95	194	167	191
	13.9%	12.1%	11.8%	8.1%	7.7%	8.5%	9.2%	6.5%	5.7%	6.3%	6.1%	2.4%	1.8%	2.0%	1.9%	2.8%	5.2%	4.7%	4.8%
ofatumumab	66	69	139	123	145	146	150	155	164	152	122	49	150	103	104	25	72	77	171
	1.6%	1.6%	3.3%	3.1%	3.6%	3.9%	4.7%	3.9%	4.3%	4.7%	3.7%	1.5%	3.7%	2.8%	2.7%	0.7%	1.9%	2.2%	4.3%
fludarabine	66	92	70	74	73	97	50	26	27	0	24	49	75	103	52	126	121	77	146
	1.6%	2.1%	1.6%	1.9%	1.8%	2.6%	1.6%	0.7%	0.7%	0.0%	0.7%	1.5%	1.8%	2.8%	1.4%	3.7%	3.2%	2.2%	3.7%
fludarabine - rituximab	219	116	70	25	48	73	150	207	191	102	97	99	50	77	78	100	121	102	122
	5.4%	2.6%	1.6%	0.6%	1.2%	2.0%	4.7%	5.2%	5.1%	3.1%	2.9%	3.0%	1.2%	2.1%	2.0%	2.9%	3.2%	2.9%	3.1%
cyclophosphamide - rituximab - vincristine	131	139	139	172	194	122	75	52	82	102	97	74	75	129	104	126	145	77	122
	3.2%	3.2%	3.3%	4.4%	4.8%	3.3%	2.4%	1.3%	2.2%	3.1%	2.9%	2.2%	1.8%	3.4%	2.7%	3.7%	3.8%	2.2%	3.1%
cyclophosphamide - doxorubicin - rituximab - vincristine	153	162	139	148	97	97	25	78	82	0	49	25	25	26	78	25	24	26	98
	3.8%	3.7%	3.3%	3.8%	2.4%	2.6%	0.8%	2.0%	2.2%	0.0%	1.5%	0.7%	0.6%	0.7%	2.0%	0.7%	0.6%	0.7%	2.5%
investigational drugs	0	0	0	49	24	49	0	78	82	127	73	124	150	103	131	126	96	77	73
	0.0%	0.0%	0.0%	1.3%	0.6%	1.3%	0.0%	2.0%	2.2%	3.9%	2.2%	3.7%	3.7%	2.8%	3.4%	3.7%	2.6%	2.2%	1.9%
azacitidine	44	23	23	25	0	0	50	52	55	51	49	49	25	52	26	75	72	51	73
	1.1%	0.5%	0.5%	0.6%	0.0%	0.0%	1.6%	1.3%	1.4%	1.6%	1.5%	1.5%	0.6%	1.4%	0.7%	2.2%	1.9%	1.4%	1.9%
carboplatin - paclitaxel	0	0	0	0	0	0	50	26	0	0	0	0	25	26	52	25	24	0	73
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.6%	0.7%	0.0%	0.0%	0.0%	0.0%	0.6%	0.7%	1.4%	0.7%	0.6%	0.0%	1.9%
cyclophosphamide - vincristine	44	69	93	49	24	24	25	78	27	25	49	0	25	77	26	50	96	77	49
	1.1%	1.6%	2.2%	1.3%	0.6%	0.7%	0.8%	2.0%	0.7%	0.8%	1.5%	0.0%	0.6%	2.1%	0.7%	1.5%	2.6%	2.2%	1.2%
cyclophosphamide - fludarabine	44	23	23	74	48	24	0	0	0	0	0	25	50	26	26	25	48	26	49
	1.1%	0.5%	0.5%	1.9%	1.2%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	1.2%	0.7%	0.7%	0.7%	1.3%	0.7%	1.2%
alemtuzumab	44	116	116	98	48	49	25	26	0	51	73	49	100	103	52	25	72	77	24
	1.1%	2.6%	2.7%	2.5%	1.2%	1.3%	0.8%	0.7%	0.0%	1.6%	2.2%	1.5%	2.5%	2.8%	1.4%	0.7%	1.9%	2.2%	0.6%
cyclophosphamide - rituximab	88	46	46	49	24	49	75	52	27	25	0	49	25	103	104	75	24	26	24
	2.2%	1.1%	1.1%	1.3%	0.6%	1.3%	2.4%	1.3%	0.7%	0.8%	0.0%	1.5%	0.6%	2.8%	2.7%	2.2%	0.6%	0.7%	0.6%
chlorambucil - rituximab	0	0	0	0	0	0	0	0	55	76	73	49	50	52	26	0	24	26	24
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.4%	2.3%	2.2%	1.5%	1.2%	1.4%	0.7%	0.0%	0.6%	0.7%	0.6%

	Jan-12	Feb-12	Mar-12	Apr-12	May-12	Jun-12	Jul-12	Aug-12	Sep-12	Oct-12	Nov-12	Dec-12	Jan-13	Feb-13	Mar-13	Apr-13	May-13	Jun-13	Jul-13
IntelliDose Patients	185	190	184	160	166	153	127	153	139	128	136	135	163	145	148	136	156	138	162
Projected Patients	4055	4388	4275	3925	4028	3709	3178	3950	3779	3247	3316	3329	4081	3747	3855	3425	3761	3529	3947
	Jan-12	Feb-12	Mar-12	Apr-12	May-12	Jun-12	Jul-12	Aug-12	Sep-12	Oct-12	Nov-12	Dec-12	Jan-13	Feb-13	Mar-13	Apr-13	May-13	Jun-13	Jul-13
cyclophosphamide	0	23	0	0	0	0	25	26	27	25	49	49	25	26	0	0	24	26	24
	0.0%	0.5%	0.0%	0.0%	0.0%	0.0%	0.8%	0.7%	0.7%	0.8%	1.5%	1.5%	0.6%	0.7%	0.0%	0.0%	0.6%	0.7%	0.6%
rituximab - vincristine	22	46	23	0	24	24	50	26	27	25	24	49	50	52	0	25	48	26	24
	0.5%	1.1%	0.5%	0.0%	0.6%	0.7%	1.6%	0.7%	0.7%	0.8%	0.7%	1.5%	1.2%	1.4%	0.0%	0.7%	1.3%	0.7%	0.6%
cyclophosphamide - doxorubicin - vincristine	88	46	23	0	0	0	0	0	0	0	24	25	25	0	0	0	0	0	24
	2.2%	1.1%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.7%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
alemtuzumab - rituximab	22	46	23	25	0	0	0	0	0	25	24	0	25	26	0	25	24	0	24
	0.5%	1.1%	0.5%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.8%	0.7%	0.0%	0.6%	0.7%	0.0%	0.7%	0.6%	0.0%	0.6%
brentuximab vedotin	22	23	23	25	24	0	25	26	27	25	0	25	0	0	0	0	24	26	24
	0.5%	0.5%	0.5%	0.6%	0.6%	0.0%	0.8%	0.7%	0.7%	0.8%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.6%	0.7%	0.6%
decitabine	22	0	0	0	0	0	25	26	0	0	0	0	25	26	26	25	24	51	24
	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.8%	0.7%	0.0%	0.0%	0.0%	0.0%	0.6%	0.7%	0.7%	0.7%	0.6%	1.4%	0.6%
carboplatin - etoposide - ifosfamide - rituximab	0	0	0	0	0	0	0	0	27	0	0	0	0	0	0	0	0	26	24
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%
cyclophosphamide - mitoxantrone - rituximab - vincristine	0	0	0	0	0	0	0	0	0	0	0	0	50	0	0	0	0	0	24
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%
bleomycin - vincristine	22	0	0	0	0	24	0	26	27	0	0	0	25	0	0	0	0	26	24
	0.5%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.7%	0.7%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%
lenalidomide - rituximab	0	0	0	25	24	24	0	0	0	0	0	0	0	0	0	25	24	26	24
	0.0%	0.0%	0.0%	0.6%	0.6%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.7%	0.6%
carboplatin - paclitaxel - rituximab	0	0	0	0	0	0	0	0	0	0	0	0	0	26	26	0	0	26	24
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.7%	0.0%	0.0%	0.7%	0.6%
cisplatin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	26	24
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%
bleomycin - cyclophosphamide - doxorubicin - etoposide - procarbazine - vincristine	0	0	0	0	0	0	25	0	0	0	0	0	0	0	0	0	0	26	24
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%
cyclophosphamide - pentostatin - rituximab	66	46	0	0	24	24	50	78	55	76	49	49	50	26	26	25	24	26	0
	1.6%	1.1%	0.0%	0.0%	0.6%	0.7%	1.6%	2.0%	1.4%	2.3%	1.5%	1.5%	1.2%	0.7%	0.7%	0.7%	0.6%	0.7%	0.0%
dasatinib	22	23	23	25	24	24	25	26	27	25	24	25	25	0	0	0	0	0	0
	0.5%	0.5%	0.5%	0.6%	0.6%	0.6%	0.8%	0.7%	0.7%	0.8%	0.7%	0.8%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
bortezomib	22	23	23	25	24	24	25	0	0	0	0	25	25	26	0	0	0	0	0
	0.5%	0.5%	0.5%	0.6%	0.6%	0.7%	0.8%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%
nilotinib	22	23	23	25	24	24	25	26	27	25	24	25	25	0	0	0	0	0	0
	0.5%	0.5%	0.5%	0.6%	0.6%	0.6%	0.8%	0.7%	0.7%	0.8%	0.7%	0.8%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - doxorubicin - etoposide - rituximab - vincristine	22	0	23	25	0	0	0	26	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.0%	0.5%	0.6%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
bleomycin - dacarbazine - doxorubicin - vinblastine	0	0	0	0	0	0	0	26	27	25	24	25	25	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.7%	0.8%	0.7%	0.7%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
fludarabine - mitoxantrone	44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
bendamustine - mitoxantrone - rituximab	44	23	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.1%	0.5%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

	Jan-12	Feb-12	Mar-12	Apr-12	May-12	Jun-12	Jul-12	Aug-12	Sep-12	Oct-12	Nov-12	Dec-12	Jan-13	Feb-13	Mar-13	Apr-13	May-13	Jun-13	Jul-13
IntelliDose Patients	185	190	184	160	166	153	127	153	139	128	136	135	163	145	148	136	156	138	162
Projected Patients	4055	4388	4275	3925	4028	3709	3178	3950	3779	3247	3316	3329	4081	3747	3855	3425	3761	3529	3947
	Jan-12	**Feb-12**	**Mar-12**	**Apr-12**	**May-12**	**Jun-12**	**Jul-12**	**Aug-12**	**Sep-12**	**Oct-12**	**Nov-12**	**Dec-12**	**Jan-13**	**Feb-13**	**Mar-13**	**Apr-13**	**May-13**	**Jun-13**	**Jul-13**
gemcitabine - paclitaxel	22	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
pralatrexate	0	0	0	0	0	0	0	26	27	25	24	25	25	0	0	25	24	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.7%	0.8%	0.7%	0.7%	0.6%	0.0%	0.0%	0.7%	0.6%	0.0%	0.0%
pemetrexed	22	23	23	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.5%	0.5%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - doxorubicin - ofatumumab - vincristine	0	0	0	25	24	24	25	26	27	25	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.6%	0.6%	0.7%	0.8%	0.7%	0.7%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - doxorubicin - rituximab	22	23	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.5%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
pentostatin	22	23	0	25	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.5%	0.0%	0.6%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
carboplatin - etoposide - ifosfamide	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cisplatin - gemcitabine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	52	50	48	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.4%	1.5%	1.3%	0.0%	0.0%
cyclophosphamide - fludarabine - methotrexate - rituximab	0	0	0	25	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.6%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ofatumumab - rituximab	0	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cetuximab	0	0	23	25	24	0	25	26	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.5%	0.6%	0.6%	0.0%	0.8%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
chlorambucil - ofatumumab	0	0	0	0	0	24	25	26	27	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.8%	0.7%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - lenalidomide - rituximab	0	0	0	0	0	0	0	0	0	0	0	0	25	26	26	25	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.7%	0.7%	0.7%	0.0%	0.0%	0.0%
bortezomib - rituximab	0	0	0	0	0	0	0	0	0	0	0	0	0	26	26	25	24	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.7%	0.7%	0.6%	0.0%	0.0%
temozolomide	0	0	0	0	0	0	0	0	0	0	0	0	0	0	26	25	24	26	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.7%	0.6%	0.7%	0.0%
gemcitabine	0	0	23	25	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.5%	0.6%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
fluorouracil	22	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cisplatin - docetaxel	22	23	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.5%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
carboplatin - gemcitabine	0	0	0	0	0	0	0	26	27	25	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.7%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
sipuleucel-t	0	0	0	0	0	0	0	26	27	25	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.7%	0.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
carboplatin - paclitaxel albumin bound	0	0	0	0	0	0	0	0	0	0	0	0	0	26	26	25	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.7%	0.7%	0.0%	0.0%	0.0%

	Jan-12	Feb-12	Mar-12	Apr-12	May-12	Jun-12	Jul-12	Aug-12	Sep-12	Oct-12	Nov-12	Dec-12	Jan-13	Feb-13	Mar-13	Apr-13	May-13	Jun-13	Jul-13
IntelliDose Patients	185	190	184	160	166	153	127	153	139	128	136	135	163	145	148	136	156	138	162
Projected Patients	4055	4388	4275	3925	4028	3709	3178	3950	3779	3247	3316	3329	4081	3747	3855	3425	3761	3529	3947
	Jan-12	**Feb-12**	**Mar-12**	**Apr-12**	**May-12**	**Jun-12**	**Jul-12**	**Aug-12**	**Sep-12**	**Oct-12**	**Nov-12**	**Dec-12**	**Jan-13**	**Feb-13**	**Mar-13**	**Apr-13**	**May-13**	**Jun-13**	**Jul-13**
cyclophosphamide - fludarabine - rituximab - vincristine	0	0	0	0	0	0	0	0	0	0	0	25	0	26	26	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.7%	0.7%	0.0%	0.0%	0.0%	0.0%
cisplatin - cytarabine - etoposide - rituximab	0	0	0	0	0	0	0	0	0	0	0	25	25	26	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - fluorouracil - methotrexate	0	0	0	0	0	0	0	0	0	0	0	25	25	26	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.6%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%
bendamustine - mitoxantrone	0	23	23	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.5%	0.5%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
bevacizumab - carboplatin - pemetrexed	0	0	0	0	0	0	0	0	27	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
docetaxel	0	0	0	0	24	0	0	0	0	0	0	0	0	0	26	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%
bendamustine - fludarabine - rituximab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	24	26	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.7%	0.0%
cytarabine - methotrexate	0	0	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cisplatin - fluorouracil	0	0	23	0	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.5%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
bleomycin - rituximab - vincristine	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
bortezomib - cyclophosphamide	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
alemtuzumab - fludarabine - melphalan	0	0	0	0	0	0	0	0	0	0	0	0	25	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
etoposide - ifosfamide - methotrexate - rituximab	0	0	0	0	0	0	0	0	0	0	0	0	25	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
bendamustine - chlorambucil - rituximab	0	0	0	0	0	0	0	0	0	0	0	25	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cisplatin - docetaxel - fluorouracil	0	0	0	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
alemtuzumab - chlorambucil	0	0	0	0	0	24	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
carboplatin	0	0	0	0	0	24	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cyclophosphamide - pentostatin	0	0	0	0	0	24	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
cisplatin - cytarabine	0	0	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.0%	0.0%	0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%